Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of DAR-901 in BCG-Primed Adults
NCT02063555Phase 1Completed
- Sponsor
- Dartmouth Health
- Start
- Feb 2014
- Primary completion
- Mar 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DAR-901 in Tuberculosis (TB) (3 arms), sponsored by Dartmouth Health. Primary endpoint: Safety at 10 months. Started Feb 2014; status: completed.
02
Drugs
DAR-901
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02063555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063555.